Related Experiment Video

Updated: May 4, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

12.8K

FoxO proteins: regulation and molecular targets in liver cancer

S Carbajo-Pescador, J L Mauriz, A García-Palomo

  • 1Institute of Biomedicine (IBIOMED), Campus Universitario, 24071, Leon, Spain. jgonga@unileon.es.

Current Medicinal Chemistry
|December 31, 2013
PubMed

Insights

Human forkhead box class O (FoxO) transcription factors are key tumor suppressors in liver cancer. Activating FoxO proteins offers a promising strategy for developing new hepatocarcinoma treatments.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Forkhead box class O (FoxO) transcription factors regulate gene expression in response to stimuli like insulin and oxidative stress.
  • FoxO proteins are implicated in metabolic processes and act as tumor suppressors by promoting cell cycle arrest and apoptosis.
  • Dysregulation of FoxO pathways is linked to poor prognosis and chemotherapy resistance in cancer patients.

Purpose of the Study:

  • To elucidate the regulatory mechanisms of FoxO proteins in liver cancer.
  • To explore the role of FoxO factors in hepatocellular carcinoma.
  • To identify potential therapeutic strategies targeting FoxO activation for hepatocarcinoma treatment.

Main Methods:

  • Review of molecular modulation of FoxO proteins via post-translational modifications (phosphorylation, acetylation, ubiquitination).
  • Analysis of FoxO interactions with key signaling pathways in liver cancer (Wnt/β-catenin, PI3K/AKT/mTOR, MAPKs).
  • Examination of FoxO3a's anti-tumor properties in hepatocellular carcinoma models.

Main Results:

  • FoxO factors' subcellular localization and DNA binding are controlled by intricate regulatory networks.
  • Low FoxO levels correlate with poor prognosis and chemoresistance in cancer.
  • FoxO3a demonstrates anti-tumor effects by upregulating pro-apoptotic genes and modulating oncogenic signaling pathways.

Conclusions:

  • FoxO proteins are crucial tumor suppressors in liver cancer, with FoxO3a showing significant anti-hepatocellular carcinoma activity.
  • Understanding FoxO regulation provides insights into novel therapeutic targets for hepatocarcinoma.
  • Developing agents that activate FoxO family members holds promise for effective hepatocarcinoma treatment.

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.5K
Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

4.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.9K